Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Thought disorder

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    77 result(s) found for: Thought disorder. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2008-005004-13 Sponsor Protocol Number: NEURAPRO-E FINAL Protocol Start Date*: 2010-10-14
    Sponsor Name:Orygen Research Centre
    Full Title: Add-on Therapie mit Omega-3 Fettsäuren bei Jugendlichen mit hohem Risiko für Schizophrenie und andere psychotische Störungen: eine Multizentren- Replikationsstudie Omega-3 Fatty Acids for Symptomat...
    Medical condition: In view of recent data and after a careful review of potentially neuroprotective treatment options in early psychotic illness, we have decided to replicate the findings of a randomized controlled t...
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-004175-23 Sponsor Protocol Number: A9451165 Start Date*: 2015-04-07
    Sponsor Name:Pfizer Japan Inc
    Full Title: A 52 weeks, open-label, multicenter study evaluating the efficacy and safety of gabapentin as adjunctive therapy in pediatric subjects who have completed the 12 weeks treatment in study A9451162.
    Medical condition: Epilepsy with partial seizures (including secondarily generalized seizures)
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2008-001732-13 Sponsor Protocol Number: SPIO_180308 Start Date*: 2008-09-03
    Sponsor Name:University of Edinburgh
    Full Title: Magnetic Resonance Imaging of Aortic Aneurysm Instability
    Medical condition: Abdominal Aortic Aneurysm disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-001779-35 Sponsor Protocol Number: 4 Start Date*: 2013-02-15
    Sponsor Name:University of Southampton
    Full Title: The effects of pregabalin augmentation of antidepressant drug on neuro-cognitive functioning in patients with generalized anxiety disorder
    Medical condition: Generalised anxiety disorder
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004873 10018105 Generalized anxiety disorder LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2008-002699-83 Sponsor Protocol Number: 31-08-248 Start Date*: 2009-01-14
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: A 52-week, Multicenter, Open-label Study to Evaluate the Effectiveness of Aripiprazole Intramuscular Depot as Maintenance Treatment in Patients with Schizophrenia "ASPIRE OPEN-LABEL" (Aripiprazole...
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039626 Schizophrenia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) FI (Completed) HU (Completed) AT (Completed) EE (Completed) DK (Prematurely Ended) FR (Completed) GB (Completed) BG (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2007-001573-28 Sponsor Protocol Number: Uni-Koeln-320 Start Date*: 2007-11-26
    Sponsor Name:Universität zu Köln
    Full Title: Prevent: Secondary Prevention of Schizophrenia. A randomized controlled trial.
    Medical condition: Persons at risk of being prodromally symptomatic of psychosis (PAR)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-004483-11 Sponsor Protocol Number: 80-83600-98-40120 Start Date*: 2016-07-08
    Sponsor Name:University Medical Center Utrecht
    Full Title: Raloxifene Augmentation in Patients with a Schizophrenia spectrum Disorder to reduce symptoms and improve cognition
    Medical condition: schizophrenia, schizoaffective, schizophreniform disorder or psychosis not otherwhise specified (DSM-IV 295.*)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10039635 Schizophrenia schizoaffective LLT
    21.1 100000004873 10039648 Schizophreniform illness LLT
    20.0 100000004873 10039632 Schizophrenia NOS LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-002676-10 Sponsor Protocol Number: 31-07-247 Start Date*: 2008-12-02
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: A 38-week, Multicenter, Randomized, Double-blind, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole (OPC-14597) as Mai...
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    14.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) EE (Completed) HU (Completed) AT (Completed) FR (Completed) BG (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-002675-27 Sponsor Protocol Number: 31-07-246 Start Date*: 2009-05-11
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole (OPC-14597) as Ma...
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039626 Schizophrenia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BG (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2014-004174-42 Sponsor Protocol Number: A9451162 Start Date*: 2015-04-06
    Sponsor Name:Pfizer Japan Inc.
    Full Title: An Open-Label, Multicenter Study Evaluating, The Efficacy, Safety And Pharmacokinetics Of Gabapentin As Adjunctive Therapy In Pediatric Subjects With Partial Seizures When Other Antiepileptics Do N...
    Medical condition: Epilepsy with partial seizures (including secondarily generalized seizures)
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-018671-20 Sponsor Protocol Number: P06384 Start Date*: 2012-08-24
    Sponsor Name:Forest Research Institute Inc., a wholly owned subsidiary of Forest Laboratories, LLC
    Full Title: A Double-Blind, Placebo-Controlled Trial of Asenapine in the Prevention of Recurrence of a Mood Episode After Stabilization of an Acute Manic/Mixed Episode in Subjects With Bipolar 1 Disorder (Phas...
    Medical condition: Bipolar 1 Disorder
    Disease: Version SOC Term Classification Code Term Level
    17.1 10037175 - Psychiatric disorders 10004939 Bipolar I disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2016-003992-23 Sponsor Protocol Number: 54135419SUI3002 Start Date*: 2017-07-26
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Sympto...
    Medical condition: Major Depressive Disorder with Imminent Risk of Suicide
    Disease: Version SOC Term Classification Code Term Level
    20.1 10037175 - Psychiatric disorders 10042458 Suicidal ideation PT
    20.0 10037175 - Psychiatric disorders 10057840 Major depression PT
    20.0 10037175 - Psychiatric disorders 10012397 Depression suicidal PT
    20.0 10037175 - Psychiatric disorders 10065604 Suicidal behaviour PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) PL (Completed) CZ (Completed) AT (Completed) LT (Completed) FR (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2004-001482-17 Sponsor Protocol Number: F1D-MC-HGKQ(b) Start Date*: 2004-10-15
    Sponsor Name:Eli Lilly and Company
    Full Title: Olanzapine Versus Divalproex and Placebo in the Treatment of Mild to Moderate Mania Associated with Bipolar I disorder.
    Medical condition: Manic or Mixed Episodes Associated with Bipolar I Disorder
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: LT (Completed)
    Trial results: View results
    EudraCT Number: 2016-000060-42 Sponsor Protocol Number: D1001066 Start Date*: 2017-03-15
    Sponsor Name:Sunovion Pharmaceuticals Inc.
    Full Title: A 6-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lurasidone (SM-13496) in Acutely Psychotic Subjects with Schizophrenia
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-003990-17 Sponsor Protocol Number: 54135419SUI3001 Start Date*: 2017-05-18
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Sympto...
    Medical condition: Major Depressive Disorder with Imminent Risk of Suicide
    Disease: Version SOC Term Classification Code Term Level
    20.1 10037175 - Psychiatric disorders 10042458 Suicidal ideation PT
    20.0 10037175 - Psychiatric disorders 10057840 Major depression PT
    20.0 10037175 - Psychiatric disorders 10012397 Depression suicidal PT
    20.0 10037175 - Psychiatric disorders 10065604 Suicidal behaviour PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SK (Completed) DE (Completed) HU (Completed) ES (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2004-004909-16 Sponsor Protocol Number: D1447C00134 Start Date*: 2005-05-03
    Sponsor Name:AstraZeneca AB
    Full Title: An International, Multi-centre, Double-blind, Randomised, Parallel-group, Placebo-controlled, Phase III study of the Efficacy and Safety of Quetiapine Fumarate (Seroquel™, single oral 300 mg or 600...
    Medical condition: Depressive episodes in bipolar disorder
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-020987-39 Sponsor Protocol Number: 31-09-266 Start Date*: 2012-10-15
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: A Long-Term Multicenter, Randomized, Double-blind, Placebocontrolled Study to Evaluate the Efficacy, Safety, and Tolerability of Aripiprazole (OPC-14597) as Maintenance Treatment in Adolescent Pati...
    Medical condition: Schizophrenia in Adolescent Patients
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2009-012031-15 Sponsor Protocol Number: 01KG0910 Start Date*: 2009-11-19
    Sponsor Name:Technische Universitaet Muenchen, vertreten durch das Klinikum rechts der Isar
    Full Title: The switch study - efficacy of early antipsychotic switch versus maintenance in patients with schizophrenia poorly responding to two weeks of antipsychotic treatment
    Medical condition: Patients with a diagnosis of schizophrenia , schizophreniform disorder or schizoaffective disorder according to DSM-IV TR criteria; experiencing an acute episode of their illness
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10039647 Schizophreniform disorder PT
    14.1 10037175 - Psychiatric disorders 10039621 Schizoaffective disorder PT
    14.1 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2007-002960-85 Sponsor Protocol Number: NN20372 Start Date*: 2008-03-18
    Sponsor Name:F.Hoffmann-La Roche Ltd
    Full Title: Randomized, double-blind, placebo-controlled add-on trial of the safety and efficacy of RO4917838 in outpatients on select atypical antipsychotics with prominent negative or disorganized thought sy...
    Medical condition: Schizophrenia - This study will be conducted to investigate whether or not administration of RO4917838 along with their current antipsychotic regimen to stable patients can lead to further improvem...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039626 Schizophrenia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) FR (Completed) AT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-005138-21 Sponsor Protocol Number: TC-5619-23-CRD-003 Start Date*: 2012-04-03
    Sponsor Name:Targacept Inc.
    Full Title: A double-blind, placebo-controlled, multicenter, parallel group study to assess efficacy, safety and tolerability of TC-5619 as augmentation therapy to improve negative symptoms and cognition in ou...
    Medical condition: Schizophrenia
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jun 07 08:06:52 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA